
    
      The primary objective of this study was to assess the treatment duration in the real life in
      2 cohorts consisting of patients treated by 200 mg once daily IV/PO tedizolid or treated by
      600 mg twice daily IV/PO (intravenous/per oral) linezolid.
    
  